Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 70 articles: HTML format

Single Articles

October 2026
1. ABIKAR A, Annayya SK, Mustafa MMS, Athalye RR, et al
   Identification of Cancer-associated Fibroblasts-specific ncRNA-mRNA/Protein Regulatory Axes in Prostate Cancer.
   Anticancer Res. 2026;46:5375-5386.
   PubMed     Abstract available
   
   
   July 2026
2. TSAI YS, Lee PH, Jou YC, Tsai HT, et al
   Two Arms-one Assisted Port Extraperitoneal Robot-assisted Radical Prostatectomy: A Simplified, Safe, Alternative Technique.
   Anticancer Res. 2026;46:4011-4020.
   PubMed     Abstract available
   
   
   June 2026
3. YAMADA Y, Matsumoto M, Ikehara M, Tsujino T, et al
   Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.
   Anticancer Res. 2026;46:3461-3472.
   PubMed     Abstract available
   
   
   
4. YAMAMOTO Y, Matsumura N, Fujimoto S, Morita T, et al
   Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer.
   Anticancer Res. 2026;46:3383-3393.
   PubMed     Abstract available
   
   
   
5. LEE J, Yoon J, Lee JY, Song YS, et al
   Milk Extracellular Vesicle-mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells.
   Anticancer Res. 2026;46:3145-3157.
   PubMed     Abstract available
   
   
   May 2026
6. RADES D, Narvaez-Wolf CA, Zwaan IC, Vestergard-Madsen C, et al
   A Reminder App for Optimizing Bladder Filling During Radiotherapy for Prostate Cancer: A Pre-study in Healthy Volunteers.
   Anticancer Res. 2026;46:2763-2770.
   PubMed     Abstract available
   
   
   April 2026
7. YANISHI M, Shimada S, Mishima T, Kinoshita H, et al
   Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2026;46:2145-2151.
   PubMed     Abstract available
   
   
   
8. WATANABE R, Shigehisa R, Kawada T, Yamamoto S, et al
   Paired-sample Analysis of ERG Expression and TMPRSS2-ERG Fusion in Treatment-induced Neuroendocrine Prostate Cancer.
   Anticancer Res. 2026;46:1929-1942.
   PubMed     Abstract available
   
   
   March 2026
9. SPRAVE T, Fauser S, Paplomatas P, Schafer H, et al
   A Real-World Evaluation of Health-Related Quality of Life Using the EQ-5D-5L Instrument in Patients Undergoing Radiotherapy for Prostate Cancer.
   Anticancer Res. 2026;46:1707-1718.
   PubMed     Abstract available
   
   
   February 2026
10. YAMADA Y, Shirafuji T, Sato K, Tsujino T, et al
    Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.
    Anticancer Res. 2026;46:1107-1116.
    PubMed     Abstract available
    
    
    
11. LIU J, Hsu CY, Lu J, Zhang LE, et al
    Prognostic Significance of PPFIA2 in Localized Prostate Cancer: Integrative Analysis and Functional Validation.
    Anticancer Res. 2026;46:757-770.
    PubMed     Abstract available
    
    
    January 2026
12. RADES D, Janssen S, Thieme C, Kristiansen C, et al
    Impact of the Pre-radiotherapy Volume of the Urinary Bladder on its Filling Status During Hypo-fractionated Treatment for Prostate Cancer.
    Anticancer Res. 2026;46:283-292.
    PubMed     Abstract available
    
    
    December 2025
13. SAMBATARO D, Gebbia V, Scrima F, Borsellino N, et al
    Exploratory Analysis of Dunning-Kruger Effect Among Oncologists Managing Prostatic Adenocarcinoma Candidates for Radionuclide Therapy.
    Anticancer Res. 2025;45:5743-5751.
    PubMed     Abstract available
    
    
    
14. KUO JH, Ou YC, Hu CY, Wu KY, et al
    Optimizing Biopsy Decisions in PI-RADS 3-4 Lesions: Integrating PSA-derived Biomarkers to Reduce Unnecessary Procedures.
    Anticancer Res. 2025;45:5709-5720.
    PubMed     Abstract available
    
    
    
15. ONISHI K, Nakai Y, Miyake M, Matsumura Y, et al
    Should Upfront Therapy With Androgen Receptor Signaling Inhibitors Be Used in All Japanese Patients With Metastatic Castration-sensitive Prostate Cancer?
    Anticancer Res. 2025;45:5595-5607.
    PubMed     Abstract available
    
    
    
16. ASANO Y, Han Q, Li S, Sato T, et al
    Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet.
    Anticancer Res. 2025;45:5799-5805.
    PubMed     Abstract available
    
    
    November 2025
17. NAKAI Y, Tanaka N, Onishi K, Goto D, et al
    The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side.
    Anticancer Res. 2025;45:5177-5184.
    PubMed     Abstract available
    
    
    October 2025
18. YUMISAKI H, Kubo N, Oike T, Kawamura H, et al
    A Dosimetric Evaluation of the Feasibility and Robustness of Ultra-hypofractionated Carbon Ion Radiotherapy Planning for the Treatment of Prostate Cancer.
    Anticancer Res. 2025;45:4453-4464.
    PubMed     Abstract available
    
    
    
19. IMAFUKU H, Terashima K, Fukunishi K, Suefuji H, et al
    Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients.
    Anticancer Res. 2025;45:4465-4472.
    PubMed     Abstract available
    
    
    
20. LEHRER S, Rheinstein PH
    PROX1 Expression Is Significantly Associated With ERG Expression and the TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2025;45:4381-4388.
    PubMed     Abstract available
    
    
    September 2025
21. NAKAI Y, Onishi K, Kagebayashi Y, Fujimoto K, et al
    Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel.
    Anticancer Res. 2025;45:3953-3960.
    PubMed     Abstract available
    
    
    August 2025
22. HATTORI A, Seki T, Kato K, Virgona N, et al
    NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway.
    Anticancer Res. 2025;45:3197-3207.
    PubMed     Abstract available
    
    
    
23. BABU YSR, Venkatachalam KV
    Methionine Deprivation-induced Cancer Cell Death and Methylation Changes in Key Genes and Gene Promoters of Prostate Cancer Cell Lines.
    Anticancer Res. 2025;45:3209-3219.
    PubMed     Abstract available
    
    
    July 2025
24. DEMIR U, Badoglu H, Cetin IN, Bener MY, et al
    A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer.
    Anticancer Res. 2025;45:3077-3087.
    PubMed     Abstract available
    
    
    
25. NGUYEN MD, Modestine JRD, Djoua Y, Gorobets O, et al
    Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series.
    Anticancer Res. 2025;45:3127-3136.
    PubMed     Abstract available
    
    
    June 2025
26. AIZAWA R, Ogata T, Goto T, Otani T, et al
    Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI.
    Anticancer Res. 2025;45:2515-2525.
    PubMed     Abstract available
    
    
    
27. NGUYEN MD, Gorobets O, Djoua YJ, Rose-Dite-Modestine J, et al
    End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report.
    Anticancer Res. 2025;45:2535-2538.
    PubMed     Abstract available
    
    
    May 2025
28. TAKASHIMA Y, Yoshii K, Tanaka M, Tashiro K, et al
    Ubiquitin-proteasome Pathway-linked Gene Signatures as Prognostic Indicators in Prostate Cancer.
    Anticancer Res. 2025;45:1825-1841.
    PubMed     Abstract available
    
    
    
29. AOKI M, Matsui H, Kurihara S, Ohtake N, et al
    Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia.
    Anticancer Res. 2025;45:2195-2204.
    PubMed     Abstract available
    
    
    April 2025
30. NAKAI Y, Onishi K, Nakahama T, Kagebayashi Y, et al
    Evaluation of Candidates for Upfront Docetaxel Therapy Among Patients With Metastatic Castration-sensitive Prostate Cancer from a Retrospective Multicenter Study (MAHOROBA study).
    Anticancer Res. 2025;45:1653-1660.
    PubMed     Abstract available
    
    
    March 2025
31. HIRATA J, Hara T, Jimbo N, Ueki H, et al
    Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies.
    Anticancer Res. 2025;45:1137-1147.
    PubMed     Abstract available
    
    
    
32. HSU JY, Ou HC, Ou YC, Lin YS, et al
    Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.
    Anticancer Res. 2025;45:1281-1289.
    PubMed     Abstract available
    
    
    
33. NIEDER C, Haukland EC, Stanisavljevic L, Mannsaker B, et al
    Radiotherapy for Bone Metastases in Patients With Excellent Performance Status: Patterns of Care and Prognostic Factors for Survival.
    Anticancer Res. 2025;45:1149-1158.
    PubMed     Abstract available
    
    
    
34. WU J, Lagunas AM, Crowe DL
    DNA Ligase 4 Inhibition Sensitizes Prostate Cancer to Immune Checkpoint Blockade In Vivo.
    Anticancer Res. 2025;45:883-896.
    PubMed     Abstract available
    
    
    February 2025
35. RADES D, Kristiansen C, Vestergaard Madsen C, Kuter JD, et al
    Bladder Volume <200 ml During a Course of Moderate Hypofractionated Irradiation in Patients With Localized Prostate Cancer.
    Anticancer Res. 2025;45:701-708.
    PubMed     Abstract available
    
    
    
36. HIROSHIGE T, Suekane H, Tokunaga T, Uegaki M, et al
    Prognostic Stratification Using Early Prostate-specific Antigen Kinetics in Men With Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2025;45:751-759.
    PubMed     Abstract available
    
    
    December 2024
37. YIN W, He P, Zou Z, Lin J, et al
    SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer.
    Anticancer Res. 2024;45:153-172.
    PubMed     Abstract available
    
    
    
38. KAMIMA T, Ueda Y, Fukunaga JI, Shimizu Y, et al
    Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based Approach Using Multiple Collimator Angles.
    Anticancer Res. 2024;44:5303-5312.
    PubMed     Abstract available
    
    
    October 2024
39. RADES D, Cremers F, Ziemann C, Splettstosser L, et al
    Changes in Bladder Volume During Radiotherapy for Prostate Cancer.
    Anticancer Res. 2024;44:4457-4463.
    PubMed     Abstract available
    
    
    
40. POULSEN TS, Lorup AN, Kongsted P, Eefsen RL, et al
    TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:4203-4211.
    PubMed     Abstract available
    
    
    September 2024
41. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    August 2024
42. PICKETT C, Karunanandaa K, Stackable K, Eaton DB Jr, et al
    Prescription Medications and Overall Survival in Metastatic Hormone Sensitive Prostate Cancer.
    Anticancer Res. 2024;44:3443-3449.
    PubMed     Abstract available
    
    
    July 2024
43. KUSTER JHS, Erb HHH, Ahrend H, Abazid A, et al
    Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide.
    Anticancer Res. 2024;44:2815-2821.
    PubMed     Abstract available
    
    
    
44. MITSUNARI K, Fukushima H, Kurata H, Harada J, et al
    Predictive Factors for Early Biochemical Recurrence Following Robot-assisted Radical Prostatectomy: The Impact of PSA Level, Gleason Score, and Pathological Tumor Stage.
    Anticancer Res. 2024;44:3149-3154.
    PubMed     Abstract available
    
    
    
45. YAMAMOTO Y, Nishimoto M, Akashi Y, Kiba K, et al
    Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:3155-3161.
    PubMed     Abstract available
    
    
    
46. HAN S, Jang S, Lee SW, Kim HY, et al
    hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3-Erk1/2 Signaling Pathway.
    Anticancer Res. 2024;44:2847-2859.
    PubMed     Abstract available
    
    
    June 2024
47. WAKITA N, Hara T, Suzuki K, Terakawa T, et al
    Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
    Anticancer Res. 2024;44:2627-2635.
    PubMed     Abstract available
    
    
    
48. WAIBEL S, Graf N, Storz J, Schultze-Seemann S, et al
    Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen.
    Anticancer Res. 2024;44:2343-2348.
    PubMed     Abstract available
    
    
    
49. WANG YJ, Hao YY, Lee DH, Guo XY, et al
    Hispidin Increases Cell Apoptosis and Ferroptosis in Prostate Cancer Cells Through Phosphatidylinositol-3-Kinase and Mitogen-activated Protein Kinase Signaling Pathway.
    Anticancer Res. 2024;44:2533-2544.
    PubMed     Abstract available
    
    
    May 2024
50. TAMBURO M, Buffettino E, Pepe P, Marletta G, et al
    Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Anticancer Res. 2024;44:2205-2210.
    PubMed     Abstract available
    
    
    April 2024
51. MASUDA H, Amemiya Y, Yagisawa N, Arai T, et al
    Association Between Acute Kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
    Anticancer Res. 2024;44:1767-1772.
    PubMed     Abstract available
    
    
    
52. KASHIWAGI E, Kawahara T, Kinoshita F, Shiota M, et al
    The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.
    Anticancer Res. 2024;44:1369-1376.
    PubMed     Abstract available
    
    
    
53. CHANG CC, Chiou JK, Lin CJ, Lu K, et al
    Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
    Anticancer Res. 2024;44:1683-1693.
    PubMed     Abstract available
    
    
    March 2024
54. HOLM I, Hernroth B, Rosander A, Tassidis H, et al
    Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
    Anticancer Res. 2024;44:953-962.
    PubMed     Abstract available
    
    
    
55. YAMAMICHI G, Kato T, Watabe T, Hatano K, et al
    Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Anticancer Res. 2024;44:879-888.
    PubMed     Abstract available
    
    
    
56. HERNANDEZ-VALENCIA CG, Rodriguez-Martinez G, Carriles-Perez AM, Gonzalez-Perez D, et al
    Antiproliferative and Antimigratory Activity of Poly-gallic Acid in Cancer Cell Lines.
    Anticancer Res. 2024;44:1201-1208.
    PubMed     Abstract available
    
    
    February 2024
57. DELL'ATTI L
    Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications.
    Anticancer Res. 2024;44:463-470.
    PubMed     Abstract available
    
    
    
58. KUROKAWA G, Mori K, Sasaki H, Nakano J, et al
    Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
    Anticancer Res. 2024;44:679-686.
    PubMed     Abstract available
    
    
    
59. SAKAMOTO S, Ando K, Pae S, Zhao X, et al
    Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:639-647.
    PubMed     Abstract available
    
    
    January 2024
60. OKA D, Sekine Y, Tsuji Y, Nakayama H, et al
    Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression.
    Anticancer Res. 2024;44:93-98.
    PubMed     Abstract available
    
    
    
61. REINIKAINEN P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer.
    Anticancer Res. 2024;44:139-150.
    PubMed     Abstract available
    
    
    December 2023
62. MIYAZAWA Y, Sekine Y, Oka D, Nakazawa S, et al
    Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer Cells.
    Anticancer Res. 2023;43:5377-5386.
    PubMed     Abstract available
    
    
    
63. MAEDA-MINAMI A, Nishikawa T, Ishikawa H, Mutoh M, et al
    Angiotensin II Receptor Blockers Cause Changes in Prostate-specific Antigen Levels: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:5629-5636.
    PubMed     Abstract available
    
    
    
64. FUKUI Y, Yamada Y, Sakamoto S, Horikoshi T, et al
    Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy.
    Anticancer Res. 2023;43:5705-5712.
    PubMed     Abstract available
    
    
    
65. SMULDERS-SRINIVASAN TK, Jenkinson SE, Brown LJ, Lenis VP, et al
    PDIA6 and Maspin in Prostate Cancer.
    Anticancer Res. 2023;43:5331-5340.
    PubMed     Abstract available
    
    
    November 2023
66. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
    The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
    Anticancer Res. 2023;43:5115-5125.
    PubMed     Abstract available
    
    
    October 2023
67. KANO H, Izumi K, Nakagawa R, Toriumi R, et al
    Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.
    Anticancer Res. 2023;43:4619-4626.
    PubMed     Abstract available
    
    
    
68. NAGATA Y, Jojima K, Matsukawa T, Tomisaki I, et al
    Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4573-4581.
    PubMed     Abstract available
    
    
    
69. KUSUHARA Y, Fukawa T, Fukumori T, Ueno Y, et al
    Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer.
    Anticancer Res. 2023;43:4627-4635.
    PubMed     Abstract available
    
    
    
70. URABE F, Kobayashi D, Iwatani K, Imai YU, et al
    The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4611-4617.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum